Results 141 to 150 of about 15,380 (223)

Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection. [PDF]

Oncologist
Procaccio L, Giordano G, Nichetti F, Milella M, Pretta A, Iacono D, Niger M, Casalino S, Vivaldi C, De Vita F, Pusceddu V, Landriscina M, Di Paolo G, Sperotto S, Masucci M, Tortora G, Bianco R, Vasile E, Zaniboni A, Miceli CC, Ongaro E, Giommoni E, Tinè G, Barsotti G, Marchesi S, Di Marco M, Ortolani S, Aprile G, Scartozzi M, Bergamo F, Melisi D, Lonardi S.   +31 more
europepmc   +1 more source

A case report of advanced pancreatic cancer patient demonstrating remarkable efficacy with liposomal irinotecan after failure of multiple-line therapies. [PDF]

Front Oncol
Yu S, Zhu H.
europepmc   +1 more source

Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma [PDF]

, 2018
Belt, Brian A, Cullinan, Darren R, DeNardo, David G, Fields, Ryan C, Gillanders, William E, Goedegebuure, Peter, Han, Booyeon J, Hawkins, William G, Jacobs, Ryan C, Linehan, David C, Nywening, Timothy M, Panni, Roheena Z, Patel, Ankit A, Sanford, Dominic E, Ye, Jian   +14 more
core   +1 more source

Real-world comparative effectiveness of FOLFIRINOX versus gemcitabine/nab-paclitaxel in metastatic pancreatic cancer: prognostic impact of metastatic site and burden in a Middle Eastern cohort. [PDF]

J Gastrointest Oncol
Eldehna WM, Elbarbry F, Shakra RA, Elrasad SA, Morsi ZA, Soaida SM, Wagdy WM, Aljohani AI, Abbas RM.   +8 more
europepmc   +1 more source

FOLFIRINOX as first-line chemotherapy in Japanese patients suffering from metastatic pancreatic cancer (KOBE FOLFIRINOX Study)

FOLFIRINOX as first-line chemotherapy in Japanese patients suffering from metastatic pancreatic cancer (KOBE FOLFIRINOX Study)
Background/aim: FOLFIRINOX (oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin) combination chemotherapy is the gold-standard therapy for advanced pancreatic cancer. In this study, FOLFIRINOX dosages for Japanese patients were established enabling FOLFIRINOX therapy optimization for efficient use.
openaire  

FOLFIRINOX in pancreatic cancer: A careful review [PDF]

Annals of Oncology, 2018
E. Una Cidon, P. Alonso
openaire   +1 more source

Impact of Germline <i>BRCA</i> Mutation Status on Antitumor Activity of Modified FOLFIRINOX in Patients With Advanced Pancreatic Cancer: An Exploratory Analysis. [PDF]

JCO Precis Oncol
Lee L, Tachibana Y, Matsuo S, Niina Y, Fujiyama T, Hisano T, Sugimoto R, Akashi T, Ogoshi K, Furukawa M.   +9 more
europepmc   +1 more source

Chemotherapy for Older Adults with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis. [PDF]

J Clin Med
Shin DW, Ahn JS, Song H, Moon SH, Lee JC.   +4 more
europepmc   +1 more source

Neoadjuvant Therapy for Localized Pancreatic Cancer. [PDF]

Cancers (Basel)
McKean J, Underwood P, Yasinzai AQK, George T, Sahin I, Fabregas J, Qumseya B, Novikov A, Chua T, Paniccia A, Hitchcock KE, Hughes S, Nassour I.   +12 more
europepmc   +1 more source

First-Line Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Real-World Outcomes and Prognostic Factors From a Vietnamese Cohort. [PDF]

Clin Med Insights Oncol
Nguyen HV, Dinh PT, Tran T, Hoang CT.
europepmc   +1 more source